FUNDAMENTALS · Fundamentals · CH Healthcare

MoonLake Immunotherapeutics (MLTX) Fundamentals 2026 — Revenue Analysis | SniperIQ

MoonLake Immunotherapeutics (MLTX) is a CH-listed Healthcare company in Biotechnology with a market capitalization of

.6B, trading at
9.10 on the NASDAQ. This SniperIQ fundamentals page covers MoonLake Immunotherapeutics's valuation, profitability (net margin 0.0%), balance-sheet quality, and AI signal context — from live market data, research only.

Market Cap
.6B
Net Margin0.0%

Full research coverage

  • 8-Quarter Revenue & Margin Trend
  • Debt Maturity & Coverage
  • Peer Valuation Comparison
  • Free Cash Flow & Owner Earnings
  • AI Signal + Institutional Flow
  • DCF Valuation Model

Frequently Asked Questions

What is MoonLake Immunotherapeutics's market cap?

MoonLake Immunotherapeutics (MLTX) has a market capitalization of approximately

.6B, trading at
9.10 on the NASDAQ. Market cap moves with the live share price.

What is MoonLake Immunotherapeutics's P/E ratio?

MoonLake Immunotherapeutics's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 5.4x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is MoonLake Immunotherapeutics?

MoonLake Immunotherapeutics runs a net profit margin of 0.0%, a gross margin of 0.0%, and an operating margin of 0.0%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

Does MoonLake Immunotherapeutics pay a dividend?

MoonLake Immunotherapeutics does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.

Is MoonLake Immunotherapeutics financially healthy?

MoonLake Immunotherapeutics carries a debt-to-equity ratio of 0.40x and a current ratio of 8.60x, with a market beta of 1.04. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is MoonLake Immunotherapeutics a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For MoonLake Immunotherapeutics (MLTX) the key facts are: market cap

.6B, 52-week range 5.95-62.75. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.

Track MoonLake Immunotherapeutics's full fundamentals live

Get MoonLake Immunotherapeutics's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.

Related: Precigen (PGEN) fundamentals · Innoviva (INVA) fundamentals · Innovage Holding (INNV) fundamentals · Vir Biotechnology (VIR) fundamentals · All stock fundamentals · AI signal library
Research Hubs: Fundamentals library · Screeners · Institutional positioning · Super investors · Daily signals · Platform comparisons